OBJECTIVE： To systematically evaluate the monitoring system for global short drugs， and provide evidence-based reference and policy recommendations for developing the short drug monitoring in China. METHODS： Relevant literatures published in PubMed， Embase， CNKI， Wanfang， VIP database from building to Apr. 3rd in 2017 were retrieved by using “Drugs （cheap drugs， essential medicines， emergency drugs） storage” “Short drugs” “Insufficient supply of drugs” “Drug shortage” as Chinese keywords， and “Drug storage” “Out-of-stock drug” “Stortage of medicine” “Stock out of medicine” as English keywords. Literatures about monitoring system for short drugs in Baidu， Google and national or regional health administration websites were collected， and general information， data collection， data validation， data reporting method， feedback and improvement measures of monitoring system were extracted. RESULTS & CONCLUSIONS： Totally 25 literatures were included， 20 national or regional health administration websites were retrieved. 11 countries and European Union had established monitoring system for short drugs. The main reporting agencies in each country were different， which were production enterprises， business enterprises and medical institutions. It was mainly reported by network. Data validation was mainly conducted by specialized departments or groups for short drugs in each country. The monitoring reporting included information of short drugs and discontinued drugs. Countermeasures in each country mainly included looking for alternative drugs， encouraging production， temporary import， looking for new or other sources of raw materials and speeding up the approval of short drugs. Besides， precautions included implementation relevant laws and guidelines for short drugs， and increasing the cooperation with non-government departments， etc. Monitoring system for short drugs needs to be further improved in China. It is suggested to establish monitoring and early warning platform for short drugs， and hierarchical intervention mechanism， improving relevant laws and developing guidelines on managing short drugs.